मूलभूत आँकड़े
| LEI | 549300EV1V8GXBV18004 |
| CIK | 1645666 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Kezar Life Sciences, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 13, 2025 |
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update •Announced FDA removal of partial clinical hold on PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis •Submitted Type C meeting request to the FDA to meet during the fourth quarter of 2025 to discuss the development plan for zetomipzomib in |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| May 13, 2025 |
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update •Reported positive topline data from PORTOLA Phase 2a clinical trial evaluating zetomipzomib in patients with autoimmune hepatitis (AIH) •Cash, cash equivalents and marketable securities totaled $114.4 million as of March 31, 2025 SOUTH SAN FRANCISCO, Calif.—May 13, 2025 — Kezar Life Sciences |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38542 Kezar Life Scie |
|
| March 25, 2025 |
EX-4.4 2 ex44-descriptionofsecuriti.htm EX-4.4 Exhibit 4.4 DESCRIPTION OF THE SECURITIES OF KEZAR LIFE SCIENCES, INC. Kezar Life Sciences, Inc. has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: (i) common stock, par value $ 0.001 per share; and (ii) preferred share purchase rights. All references to the “we,” “our,” or “us” refer to Kezar |
|
| March 25, 2025 |
Topline Results from the PORTOLA Phase 2a Trial in Autoimmune Hepatitis (AIH) Exhibit 99. |
|
| March 25, 2025 |
Executive Employment Agreement, between the Company and Mar Exhibit 10.13 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of March 20, 2025 (the “Effective Date”), between Marc L. Belsky (“Executive”) and Kezar Life Sciences, Inc. (the “Company”). Certain capitalized terms in this Agreement are defined in Article 7. On the Effective Date, this Agreement shall amend, restate and supersede the Prior Ag |
|
| March 25, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Kezar Life Sciences, Inc. |
|
| March 25, 2025 |
Non-Employee Director Compensation Policy. Exhibit 10.11 Kezar Life Sciences, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of Kezar Life Sciences, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “ |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 25, 2025 |
ment Agreement, between the Company and Mark Schiller, dated as of Exhibit 10.14 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of March 20, 2025 (the “Effective Date”), between Mark Schiller (“Executive”) and Kezar Life Sciences, Inc. (the “Company”). Certain capitalized terms in this Agreement are defined in Article 7. On the Effective Date, this Agreement shall amend, restate and supersede the Prior Agr |
|
| March 25, 2025 |
ezar Life Sciences, Inc. Insider Trading Policy. Exhibit 19.1 Kezar Life Sciences, Inc. Insider Trading Policy I.Introduction During the course of your employment, directorship or consultancy with Kezar Life Sciences, Inc. (the “Company”), you may receive important information that is not yet publicly available (“inside information”), about the Company or about other publicly traded companies with which the Company has business dealings. Because |
|
| March 25, 2025 |
Exhibit 99.1 Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results Company-hosted conference call and webcast to be held today at 8:00 a.m. ET •Zetomipzomib treatment results in steroid-sparing biochemical remissions i |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 27, 2025 |
teachininvestorevent FEBRUARY 27, 2025 VIRTUAL KOL INVESTOR EVENT Exhibit 99.1 Forward-Looking Statements and Topline Data Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “should,” “expect,” “believe”, “plan” and similar expressions (as well as other words or expressions refere |
|
| February 14, 2025 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No. |
|
| February 7, 2025 |
KEZAR LIFE SCIENCES, INC. 4000 Shoreline Court, Suite 300 South San Francisco, California 94080 (650) 822-5600 February 7, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Dickerson RE: Kezar Life Sciences, Inc. Registration Statement on Form S-3 File No. 333-284712 Acceleration Request Requ |
|
| February 5, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Kezar Life Sciences, Inc. |
|
| February 5, 2025 |
As filed with the Securities and Exchange Commission on February 5, 2025 Table of Contents As filed with the Securities and Exchange Commission on February 5, 2025 Registration No. |
|
| February 5, 2025 |
Form of Indenture, between the Company and one or more trustees to be named. Exhibit 4.3 KEZAR LIFE SCIENCES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificat |
|
| January 10, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 3, 2024 |
Exhibit 4.1 AMENDMENT NO. 1 TO RIGHTS AGREEMENT This AMENDMENT NO. 1 TO RIGHTS AGREEMENT, dated as of December 3, 2024 (this “Amendment”), is made and entered into by and between Kezar Life Sciences, Inc., a Delaware corporation (the “Company”), and Computershare Trust Company, N.A., a federally chartered trust company, as rights agent (the “Rights Agent”). Except as otherwise provided herein, cap |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 03, 2024 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 14, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 12, 2024 |
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update • Topline data from PORTOLA Phase 2a clinical trial evaluating zetomipzomib in patients with autoimmune hepatitis (AIH) expected in first half 2025 • Cash, cash equivalents and marketable securities totaled $148 million as of September 30, 2024 SOUTH SAN FRANCISCO, Calif.—November 12, 2024 — |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ———————————————— FORM 8-A/A ———————————————— FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ———————————————— Kezar Life Sciences, Inc. (Exact name of Registrant as specified in its charter) ———————————————— Delaware 47-3366145 (State of other jurisdicti |
|
| October 28, 2024 |
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split Exhibit 99.1 Kezar Life Sciences Announces 1-for-10 Reverse Stock Split SOUTH SAN FRANCISCO, Calif., Oct. 28, 2024 – Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ra |
|
| October 28, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KEZAR LIFE SCIENCES, INC. Kezar Life Sciences, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify as follows: First: The name of the Corporation is Kezar Life Sciences, Inc. Second: The date of filing the original Certificate of In |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 17, 2024 |
Exhibit 4.1 KEZAR LIFE SCIENCES, INC. and COMPUTERSHARE TRUST COMPANY, N.A., as Rights Agent RIGHTS AGREEMENT October 17, 2024 TABLE OF CONTENTS Page SECTION 1. CERTAIN DEFINITIONS 1 SECTION 2. APPOINTMENT OF RIGHTS AGENT 8 SECTION 3. ISSUANCE OF RIGHTS 9 SECTION 4. FORM OF RIGHT CERTIFICATES 11 SECTION 5. COUNTERSIGNATURE AND REGISTRATION 12 SECTION 6. TRANSFER, SPLIT UP, COMBINATION AND EXCHANGE |
|
| October 17, 2024 |
Exhibit 99.1 Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update • PORTOLA Phase 2a clinical trial in patients with autoimmune hepatitis (AIH) to continue without modification following review by Independent Data Monitoring Committee (IDMC); reiterating guidance of topline data in first half 2 |
|
| October 17, 2024 |
Exhibit 3.1 CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES AND PRIVILEGES OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF KEZAR LIFE SCIENCES, INC. The undersigned, Marc Belsky, does hereby certify: 1. That he is duly elected and acting Chief Financial Officer of Kezar Life Sciences, Inc. a Delaware corporation (the “Corporation”). 2. That pursuant to the authority conferred upon the Board |
|
| October 17, 2024 |
Exhibit 99.2 Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan SOUTH SAN FRANCISCO, Calif., Oct. 17, 2024 – Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the “Bo |
|
| October 17, 2024 |
Entry into a Material Definitive Agreement, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Kezar Life Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 47-3366145 (State of other jurisdiction of incorporation or organization) (I.R.S. Employer I.D. No.) 4000 S |
|
| October 10, 2024 |
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal Exhibit 99.1 Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal SOUTH SAN FRANCISCO, Calif., October 10, 2024— Kezar Life Sciences, Inc. (“Kezar” or the “Company”) (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it has received an unsolicited, non-binding proposal fro |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2024 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 8, 2024 |
KZR / Kezar Life Sciences, Inc. / TANG CAPITAL MANAGEMENT LLC Activist Investment SC 13D 1 g107240sc13d.htm SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the securities exchange act of 1934 (amendment no. )* Kezar Life Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 49372L100 (CUSIP Number) Kevin Tang 4747 Executive Drive, Suite 210 San Diego, CA 92121 (Name, Address and Telephone Number of Per |
|
| October 4, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 04, 2024 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 4, 2024 |
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis Exhibit 99.1 Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis SOUTH SAN FRANCISCO, Calif., Oct. 4, 2024 – Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it was informed via teleconference with the U.S. Food and Dru |
|
| September 30, 2024 |
Exhibit 99.1 Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 – Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced the voluntary |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 13, 2024 |
Exhibit 10.1 Execution Version Certain identified information has been excluded from the exhibit because it is both not material and is the type that the Registrant treats as private or confidential. Triple asterisks [***] denote exclusions. AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENT This AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENT (this “Amendment”) is entered into as of Ju |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| August 13, 2024 |
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update • Enrollment completed in PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis; revising guidance of topline data to first half 2025 • PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis currently enrolling; reiterating gu |
|
| June 21, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2024 |
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update • PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 • PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 22, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-261774 PROSPECTUS SUPPLEMENT (To Prospectus dated May 5, 2023) $24,800,000 Common Stock We previously entered into a certain sales agreement, or the sales agreement, with Cowen and Company, LLC, or TD Cowen, acting as sales agent for the offer and sale of our common stock, having an aggregate offering price of up to $68,347,416. As of March 20, |
|
| March 14, 2024 |
As filed with the Securities and Exchange Commission on March 14, 2024 As filed with the Securities and Exchange Commission on March 14, 2024 Registration No. |
|
| March 14, 2024 |
P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38542 Kezar Life Sc |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 14, 2024 |
Incentive Compensation Recoupment Policy. Exhibit 97.1 Kezar Life Sciences, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Kezar Life Sciences, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Poli |
|
| March 14, 2024 |
Non-Employee Director Compensation Policy. Exhibit 10.11 Kezar Life Sciences, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of Kezar Life Sciences, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “ |
|
| March 14, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Kezar Life Sciences, Inc. |
|
| March 14, 2024 |
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update • PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 • PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of topline data in mid-2025 • KZR-261 dose escalation study currently enrolling ninth cohort; data update by year-end • Cash, cash equivalents and marketable securities totaled $201. |
|
| March 14, 2024 |
Description of the Company’s Securities. Exhibit 4.2 DESCRIPTION OF THE SECURITIES OF KEZAR LIFE SCIENCES, INC. The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries. You should also refer to the amended and restated certificate of incorporation and the amended and restated bylaws, which are included as an exhibit to our Annual |
|
| February 14, 2024 |
EX-99.A 2 ss3005727ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. 1 to the Statement on Schedule 13G, dated December 31, 2023 (this “Schedule 13G”), with respect to the Common Stock, $0.001 par value per share, of Kezar Life Sciences, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Ru |
|
| February 14, 2024 |
KZR / Kezar Life Sciences, Inc. / Avidity Partners Management LP Passive Investment SC 13G/A 1 d1098032313g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Kezar Life Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 49372L100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 14, 2024 |
KZR / Kezar Life Sciences, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 ss3005727sc13ga.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kezar Life Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 49372L100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statem |
|
| February 13, 2024 |
KZR / Kezar Life Sciences, Inc. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d1096318013g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Kezar Life Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 49372L100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 13, 2024 |
KZR / Kezar Life Sciences, Inc. / Prosight Management, LP - SC 13G/A Passive Investment SC 13G/A 1 d751179dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* KEZAR LIFE SCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 49372L100 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the a |
|
| January 22, 2024 |
KZR / Kezar Life Sciences, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) KEZAR LIFE SCIENCES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 49372L100 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate th |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2024 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 4, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 01, 2023 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 13, 2023 |
Exhibit 10.2 October 2, 2023 John F. Fowler Address Re: Separation and Consulting Agreement Dear John: This separation and consulting agreement (the “Agreement”) summarizes the terms of your separation from Kezar Life Sciences, Inc. (the “Company”) and sets forth the severance benefits offered to you to help in this transition. 1. Employment Status and Final Payments. (a) Separation Date. You here |
|
| November 13, 2023 |
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update • Strategic restructuring extends cash runway to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis • Collaboration and license agreement with Everest Medicines to develop and commercialize zetomipzomib in Greater China, South Korea and Southeast Asia • Ke |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 13, 2023 |
Separation Agreement, between the Company and Noreen Henig, M.D., dated October 23, 2023. Exhibit 10.3 October 6, 2023 Noreen Roth Henig, M.D. Address Re: Separation Agreement Dear Dr. Henig: This separation agreement (the “Agreement”) summarizes the terms of your separation from Kezar Life Sciences, Inc. (the “Company”) and sets forth the severance benefits offered to you to help in this transition. 1. Employment Status and Final Payments. (a) Separation Date. Your last day of work wi |
|
| November 13, 2023 |
Exhibit 10.4 Execution Version Certain identified information has been excluded from the exhibit because it is both not material and is the type that the Registrant treats as private or confidential. Triple asterisks [***] denote exclusions. COLLABORATION AND LICENSE AGREEMENT by and between KEZAR LIFE SCIENCES, INC., EVEREST MEDICINES II (HK) LIMITED, and solely for purposes of SECTION 2.8.4 (Eve |
|
| November 13, 2023 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of November 7, 2023 (the “Effective Date”), between Christopher J. Kirk, Ph.D. (“Executive”) and KEZAR LIFE SCIENCES, INC. (the “Company”). Certain capitalized terms used in this Agreement are defined in Article 7. RECITALS A. The Company is a biopharmaceutical company. B. The Company |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 3, 2023 |
Exhibit 99.1 Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer • Strategic realignment to focus capital resources on clinical programs and reduce workforce by approximately 41% • Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzo |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2023 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 21, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 21, 2023 |
Exhibit 99.1 Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia • Partnership with Everest Medicines will address a critical unmet medical need for patients with active lupus nephritis in Asia • Kezar is eligible to receive up to $132.5 milli |
|
| August 17, 2023 |
KZR / Kezar Life Sciences Inc / Morningside Venture Investments Ltd - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Kezar Life Sciences, Inc. (Name of issuer) Common Stock, par value $0.001 per share (Title of class of securities) 49372L100 (CUSIP number) Morningside Venture Investments Limited C/O THC Management Services S.A.M. 2nd Floor, Le Prince De Galles |
|
| August 17, 2023 |
EX-99.1 2 d524248dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party. MORNINGS |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 10, 2023 |
Advisor Agreement between the Company and Christopher Kirk, Ph.D., dated April 22, 2023. Exhibit 10.1 ADVISOR AGREEMENT This Advisor Agreement (“Agreement”) is entered into as of April 22, 2023 (the “Effective Date”) between Kezar Life Sciences, Inc. (the “Company”), a Delaware corporation, and Christopher Kirk, Ph.D. (“Consultant”). Company and the Consultant are referred to herein individually as “Party,” and collectively as the “Parties.” Whereas, Consultant resigned from his posit |
|
| August 10, 2023 |
Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update • PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis and PORTOLA Phase 2a clinical trial evaluating zetomipzomib in autoimmune hepatitis are both open for enrollment • KZR-261 dose escalation study continues to progress and display a favorable safety and toler |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 21, 2023 |
KZR / Kezar Life Sciences Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 KEZAR LIFE SCIENCES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 49372L100 (CUSIP Number) JUNE 16, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whi |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 16, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KEZAR LIFE SCIENCES, INC. Kezar Life Sciences, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify as follows: First: The name of the Corporation is Kezar Life Sciences, Inc. Second: The date of filing the original Certificate of In |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 11, 2023 |
As filed with the Securities and Exchange Commission on May 11, 2023 As filed with the Securities and Exchange Commission on May 11, 2023 Registration No. |
|
| May 11, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Kezar Life Sciences, Inc. |
|
| May 11, 2023 |
Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update • PALIZADE Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis on track to initiate in first half of 2023 • KZR-261 dose escalation study continues to progress; the dose expansion study expected to initiate in second half of 2023 • Cash, cash equivalents and marketable securiti |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2023 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| April 21, 2023 |
KZR / Kezar Life Sciences Inc / Prosight Management, LP - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* KEZAR LIFE SCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 49372L100 (CUSIP Number) April 11, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| April 21, 2023 |
JOINT FILING AGREEMENT April 20, 2023 EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT April 20, 2023 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (includ |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| March 14, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Kezar Life Sciences, Inc. |
|
| March 14, 2023 |
Exhibit 10.20 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is made as of November 1, 2022, by and between GNS SOUTH TOWER, LP, a Delaware limited partnership (“Landlord”), and KEZAR LIFE SCIENCES, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord, as successor-in-interest to AP3-SF1 4000 Shoreline, LLC, and Tenant are parties to that certain Lease dated Aug |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38542 Kezar Life Scie |
|
| March 14, 2023 |
As filed with the Securities and Exchange Commission on March 14, 2023 POS AM Table of Contents As filed with the Securities and Exchange Commission on March 14, 2023 Registration No. |
|
| March 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 14, 2023 |
As filed with the Securities and Exchange Commission on March 14, 2023 POSASR Table of Contents As filed with the Securities and Exchange Commission on March 14, 2023 Registration No. |
|
| March 14, 2023 |
Exhibit 99.1 Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update • PALIZADE Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis to initiate in first half of 2023 • KZR-261 dose escalation study currently enrolling sixth cohort; the dose expansion study expected to initiate in second half of 2023 • Company to host a virtual Rese |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 14, 2023 |
KZR / Kezar Life Sciences Inc / ORBIMED ADVISORS LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Kezar Life Sciences, Inc. |
|
| February 14, 2023 |
KZR / Kezar Life Sciences Inc / BB BIOTECH AG - SC 13G/A Passive Investment |
|
| February 14, 2023 |
EX-99.B 2 d408330dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated December 31, 2022 (the “Schedule 13G”), with respect to the Common Stock, $0. |
|
| February 14, 2023 |
KZR / Kezar Life Sciences Inc / Avidity Partners Management LP Passive Investment SC 13G/A 1 d912790713g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kezar Life Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 49372L100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| February 13, 2023 |
KZR / Kezar Life Sciences Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d992877613g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kezar Life Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 49372L100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| January 31, 2023 |
KZR / Kezar Life Sciences Inc / FRANKLIN RESOURCES INC Passive Investment SC 13G/A 1 keza22a11.htm CUSIP NO. 49372L100 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kezar Life Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 49372L100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this |
|
| January 17, 2023 |
KZR / Kezar Life Sciences Inc / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 KZRSC13GA2023.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) KEZAR LIFE SCIENCES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 49372L100 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires filing of this statement) Check the ap |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2023 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 10, 2022 |
Executive Employment Agreement between the Company and Nick Mordwinkin, Ph.D., dated July 11, 2022. Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into as of July 11, 2022 (the ?Effective Date?), between Nick Mordwinkin, Ph.D. (?Executive?) and KEZAR LIFE SCIENCES, INC. (the ?Company?). Certain capitalized terms used in this Agreement are defined in Article 7. RECITALS A. The Company is a biopharmaceutical company. B. The Company des |
|
| November 10, 2022 |
Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update ? Presented positive complete results from the MISSION Phase 2 trial evaluating zetomipzomib in patients with lupus nephritis at ASN?s Kidney Week 2022 Annual Meeting ? Received FDA clearance of IND for zetomipzomib for the treatment of autoimmune hepatitis ? Cash, cash equivalents and market |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2022 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 3, 2022 |
Exhibit 99.1 Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting • Zetomipzomib added to stable background therapy reduced proteinuria by 50% or greater (ORR) in 11 of 17 patients (64.7%) reaching end of treatment at Week 25. This benefit occurred with a 53% mean reduction of backg |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 75 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 11, 2022 |
Exhibit 10.1 Kezar Life Sciences, Inc. 2022 Inducement Plan Adopted by the Board of Directors: April 13, 2022 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5 |
|
| August 11, 2022 |
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update ? Announced positive topline results from the MISSION Phase 2 Trial evaluating zetomipzomib for the treatment of patients with lupus nephritis ? Appointed Nick Mordwinkin, Pharm.D., Ph.D. as Chief Business Officer ? Cash, cash equivalents and marketable securities totaled $306.8 million as o |
|
| August 11, 2022 |
Exhibit 10.2 Kezar Life Sciences, Inc. Stock Option Grant Notice (2022 Inducement Plan) Kezar Life Sciences, Inc. (the ?Company?), pursuant to its 2022 Inducement Plan (the ?Plan?), hereby grants to Optionholder an option to purchase the number of shares of the Company?s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock Option Grant |
|
| July 11, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2022 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 27, 2022 |
Exhibit 99.2 Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis ? 11 of 17 patients (64.7%) achieved an overall renal response of 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months ? 6 of 17 patients (35.2%) achieved a complete renal response, including a UPCR |
|
| June 27, 2022 |
INVESTOR & ANALYST EVENT JUNE 27, 2022 Exhibit 99.1 Forward-Looking Statements and Topline Data Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “should,” “expect,” “believe”, “plan” and similar expressions (as well as other words or expressions referencing future events, condit |
|
| June 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 23, 2022 |
KZR / Kezar Life Sciences Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 KEZAR LIFE SCIENCES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 49372L100 (CUSIP Number) JUNE 17, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whi |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 13, 2022 |
KZR / Kezar Life Sciences Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 12, 2022 |
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update ? Topline data from MISSION Phase 2 trial of zetomipzomib for the treatment of lupus nephritis expected in June 2022, consistent with previous guidance ? KZR-261 continues to enroll patients with solid tumors in Phase 1 dose-escalation trial ? Company to host virtual Investor and Analyst Day |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 75 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 03, 2022 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 3, 2022 |
Exhibit 99.1 Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis ? Most patients saw clinically meaningful improvements in the primary endpoint measure of Total Improvement Score (TIS), but no differentiation from placebo was observed ? Zetomipzomib demonstrates a favorable safety and tolerability profile, including in the PRESI |
|
| April 26, 2022 |
DEFA14A 1 kzr-defa14a20220426.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| April 26, 2022 |
DEF 14A 1 kzr-def14a20220615.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| March 17, 2022 |
EX-FILING FEES 4 kzr-exfilingfees8.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Kezar Life Sciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amo |
|
| March 17, 2022 |
As filed with the Securities and Exchange Commission on March 17, 2022 As filed with the Securities and Exchange Commission on March 17, 2022 Registration No. |
|
| March 17, 2022 |
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update Exhibit 99.1 Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update ? Topline data from two Phase 2 trials of KZR-616 expected in second quarter of 2022 ? Zetomipzomib assigned as nonproprietary name for lead candidate, KZR-616 ? Cash, cash equivalents and marketable securities totaled $208.4 million as of year-end 2021 SOUTH SAN FRANCISCO, Calif. ? (BUSINESS |
|
| March 17, 2022 |
Exhibit 10.17 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this ?Agreement?) dated as of November 4, 2021 (the ?Effective Date?) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (?Oxford?), as collateral a |
|
| March 17, 2022 |
Non-Employee Director Compensation Policy. Exhibit 10.9 Kezar Life Sciences, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the ?Board?) of Kezar Life Sciences, Inc. (the ?Company?) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Director Compensation Policy (this ?P |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38542 Kezar Life Scie |
|
| March 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 Kezar Life Sciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38542 47-3366145 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 17, 2022 |
Exhibit 10.4 Kezar Life Sciences, Inc. Restricted Stock Unit Grant Notice (2018 Equity Incentive Plan) Kezar Life Sciences, Inc. (the ?Company?), pursuant to its 2018 Equity Incentive Plan (the ?Plan?), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company?s Common Stock (?Restricted Stock Units?) set forth below (the ?Award?). The Award is subject to a |
|
| February 14, 2022 |
KZR / Kezar Life Sciences Inc / Logos Global Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Kezar Life Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 49372L100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 11, 2022 |
KZR / Kezar Life Sciences Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* KEZAR LIFE SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 49372L100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 4, 2022 |
KZR / Kezar Life Sciences Inc / FRANKLIN RESOURCES INC Passive Investment keza21in.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 49372L100 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kezar Life Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 49372L100 (CUSIP Number) December 31, 2021 (Date of Even |
|
| January 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commissi |
|
| January 3, 2022 |
KZR / Kezar Life Sciences Inc / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 20, 2021 |
EXHIBIT 4.8 KEZAR LIFE SCIENCES, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF KEZAR LIFE SCIENCES, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of between KEZAR LIFE SCIENCES, INC., a Delaware corporation (the ?Company?) and , a [corporation] [national banking association] organized and exist |
|
| December 20, 2021 |
Exhibit 4.5 KEZAR LIFE SCIENCES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 S |
|
| December 20, 2021 |
EXHIBIT 4.7 KEZAR LIFE SCIENCES, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF KEZAR LIFE SCIENCES, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of between KEZAR LIFE SCIENCES, INC., a Delaware corporation (the ?Company?) and , a [corporation] [national banking association] organized and existing under |
|
| December 20, 2021 |
As filed with the Securities and Exchange Commission on December 20, 2021 Table of Contents As filed with the Securities and Exchange Commission on December 20, 2021 Registration No. |
|
| December 20, 2021 |
Exhibit 1.2 KEZAR LIFE SCIENCES, INC. $200,000,000 SALES AGREEMENT December 20, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Kezar Life Sciences, Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of |
|
| December 20, 2021 |
EXHIBIT 4.9 KEZAR LIFE SCIENCES, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF KEZAR LIFE SCIENCES, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of between KEZAR LIFE SCIENCES, INC., a Delaware corporation (the ?Company?) and , a [corporation] [national banking association] organized and exist |
|
| December 20, 2021 |
Termination of a Material Definitive Agreement, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commis |
|
| December 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commiss |
|
| November 19, 2021 |
Sales Agreement dated as of November 19, 2021, between the Company and Cowen and Company, LLC. Exhibit 1.1 KEZAR LIFE SCIENCES, INC. $100,000,000 SALES AGREEMENT November 19, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Kezar Life Sciences, Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of |
|
| November 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2021 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commis |
|
| November 19, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-248752 PROSPECTUS SUPPLEMENT (To Prospectus Dated September 23, 2020) $100,000,000 Common Stock We have entered into a sales agreement, or the sales agreement, with Cowen and Company LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with t |
|
| November 15, 2021 |
November 15, 2021 Uniquely Powerful Approaches to Tackling the Toughest Diseases SELECTIVE TARGETS. |
|
| November 15, 2021 |
Exhibit 99.2 Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis ? KZR-616 demonstrates clinically meaningful benefit in patients with lupus nephritis, with 4 out of 5 patients achieving either a partial or complete renal response at end of treatment ? KZR-616 maintained a favorable safety and tolerability profile over the six-month treatme |
|
| November 15, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commis |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 75 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commiss |
|
| November 9, 2021 |
Kezar Reports Third Quarter Financial Results and Provides Business Update Exhibit 99.1 Kezar Reports Third Quarter Financial Results and Provides Business Update ? Target enrollment met in the MISSION Phase 2 trial evaluating KZR-616 for lupus nephritis ? First patient dosed in Phase 1 trial of KZR-261 for the treatment of advanced solid tumor malignancies ? Company to host virtual Investor and Analyst Day on Monday, November 15, 2021, at 4:30 p.m. ET to discuss KZR-616 |
|
| August 12, 2021 |
Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates Exhibit 99.1 Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates ? KZR-616 MISSION Phase 1b study results support continued development for multiple immune mediated diseases ? Investigational new drug (IND) application filed for first-in-class protein secretion inhibitor, KZR-261 ? Expertise in autoimmune drug development added with appointment of Micki Klear |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 75 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commissi |
|
| July 29, 2021 |
KZR / Kezar Life Sciences Inc / Logos Global Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Kezar Life Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 49372L100 (CUSIP Number) July 19, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| June 30, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commission |
|
| June 2, 2021 |
Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021 Exhibit 99.1 Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021 ? KZR-616 demonstrates improvement across all exploratory efficacy measures and is observed to be well-tolerated up to 75 mg subcutaneously once weekly for 13 weeks. ? The MISSION Phase 1b data support the development of KZR-616 in multiple immune-mediated diseases. ? Conference call and webcast to |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| June 2, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commission |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commission |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commission |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 75 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| May 12, 2021 |
Kezar Life Sciences Reports First Quarter Financial Results and Provides Business Updates Exhibit 99.1 Kezar Life Sciences Reports First Quarter Financial Results and Provides Business Updates ? KZR-616 clinical development in three severe autoimmune diseases is advancing with several data readouts expected in 2021 and 2022 ? KZR-261 IND submission expected mid-2021, with Phase 1 trial in solid tumors expected to initiate before year-end ? Cash, cash equivalents and marketable securiti |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| March 11, 2021 |
As filed with the Securities and Exchange Commission on March 11, 2021 Registration No. |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38542 Kezar Life Scie |
|
| March 11, 2021 |
Non-Employee Director Compensation Plan. EX-10.9 2 kzr-ex1098.htm EX-10.9 Exhibit 10.9 Kezar Life Sciences, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of Kezar Life Sciences, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Dire |
|
| March 11, 2021 |
Exhibit 99.1 Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates ? KZR-616 clinical development in three severe autoimmune diseases is advancing with several data readouts expected in 2021 and 2022, subject to developments in the ongoing COVID-19 pandemic. ? Upcoming poster presentations at AACR validate that inhibition of Sec61 with a small |
|
| March 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commissio |
|
| February 16, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party. MORNINGSIDE VENTURE INVESTMENTS LTD. By: /s/ |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Kezar Life Sciences, Inc. (Name of issuer) Common Stock, par value $0.001 per share (Title of class of securities) 49372L100 (CUSIP number) Morningside Venture Investments Limited C/O THC Management Services S.A.M. 2nd Floor, Le Prince De Galles 3-5 Aven |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Kezar Life Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 49372L100 (CUSIP Number) December |
|
| February 12, 2021 |
SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* KEZAR LIFE SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 49372L100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2021 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commissi |
|
| November 5, 2020 |
Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates Exhibit 99.1 Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates • FDA grants two Orphan Drug Designations to KZR-616 for the treatment of Dermatomyositis (DM) and Polymyositis (PM) • KZR-616 clinical and pre-clinical data continues to support its potential to positively affect multiple drivers of immune-mediated diseases • KZR-261 IND submission on-track |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commiss |
|
| November 5, 2020 |
75 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| September 23, 2020 |
424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-248752 PROSPECTUS $50,000,000 Common Stock We have entered into a sales agreement with Cowen and Company LLC, or Cowen, relating to shares of our common stock offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $50,000 |
|
| September 21, 2020 |
Company Acceleration Request KEZAR LIFE SCIENCES, INC. 4000 Shoreline Court, Suite 300 South San Francisco, CA 94080 September 21, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Deanna Virginio Re: Kezar Life Sciences, Inc. Registration Statement on Form S-3 File No. 333-248752 Acceleration Request Requested Da |
|
| September 11, 2020 |
Form of Indenture, between the Company and one or more trustees to be named. EX-4.5 Exhibit 4.5 KEZAR LIFE SCIENCES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certific |
|
| September 11, 2020 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.8 EXHIBIT 4.8 KEZAR LIFE SCIENCES, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF KEZAR LIFE SCIENCES, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between KEZAR LIFE SCIENCES, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized an |
|
| September 11, 2020 |
Sales Agreement dated as of September 11, 2020, between the Company and Cowen and Company, LLC. EX-1.2 Exhibit 1.2 KEZAR LIFE SCIENCES, INC. $50,000,000 SALES AGREEMENT September 11, 2020 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Kezar Life Sciences, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the t |
|
| September 11, 2020 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.7 EXHIBIT 4.7 KEZAR LIFE SCIENCES, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF KEZAR LIFE SCIENCES, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between KEZAR LIFE SCIENCES, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existin |
|
| September 11, 2020 |
S-3 As filed with the Securities and Exchange Commission on September 11, 2020 Registration No. |
|
| September 11, 2020 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.9 EXHIBIT 4.9 KEZAR LIFE SCIENCES, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF KEZAR LIFE SCIENCES, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between KEZAR LIFE SCIENCES, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized an |
|
| August 6, 2020 |
75 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commissio |
|
| August 5, 2020 |
Exhibit 99.1 Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update Conference call and webcast today at 4:30pm EDT SAN FRANCISCO, Calif., August 5, 2020 - Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced |
|
| June 26, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2020 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commission |
|
| June 16, 2020 |
Certain Defined Terms Used in Lock-up Agreement EXHIBIT 99.2 June 7, 2020 Jefferies LLC Cowen and Company, LLC As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Cowen and Company, LLC 599 Lexington Avenue, 27th Floor New York, New York 10022 c/o William Blair & Company, L.L.C. 150 N. Riverside Plaza Chicago, Illinois 60606 RE: Kezar Life Sciences, Inc. (the “Company”) Ladies & Gentl |
|
| June 16, 2020 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party. MORNINGSIDE VENTURE INVESTMENTS LTD. By: /s/ |
|
| June 16, 2020 |
KZR / Kezar Life Sciences, Inc. / Morningside Venture Investments Ltd - SC 13D/A Activist Investment CUSIP No. 49372L100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kezar Life Sciences, Inc. (Name of issuer) Common Stock, par value $0.001 per share (Title of class of securities) 49372L100 (CUSIP number) Morningside Venture Investments Limited C/O THC Management Services S.A.M. 2nd Floor, Le Princ |
|
| June 16, 2020 |
Certain Defined Terms Used in Lock-up Agreement EXHIBIT 99.3 June 7, 2020 Jefferies LLC Cowen and Company, LLC As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Cowen and Company, LLC 599 Lexington Avenue, 27th Floor New York, New York 10022 c/o William Blair & Company, L.L.C. 150 N. Riverside Plaza Chicago, Illinois 60606 RE: Kezar Life Sciences, Inc. (the “Company”) Ladies & Gentl |
|
| June 10, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commiss |
|
| June 10, 2020 |
EX-99.1 4 d942082dex991.htm EX-99.1 Exhibit 99.1 Kezar Announces Pricing of a Public Offering of $46.7 million of Common Stock and Pre-Funded Warrants SOUTH SAN FRANCISCO, Calif., June 8, 2020 — Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today ann |
|
| June 10, 2020 |
EX-1.1 Exhibit 1.1 7,590,909 Shares of Common Stock and Pre-Funded Warrants to Purchase 909,091 Shares of Common Stock Kezar Life Sciences, Inc. UNDERWRITING AGREEMENT June 8, 2020 JEFFERIES LLC COWEN AND COMPANY, LLC WILLIAM BLAIR & COMPANY, L.L.C As Representatives of the Several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o COWEN AND COMPANY, LLC 599 Lexington A |
|
| June 10, 2020 |
7,590,909 Shares of Common Stock Pre-Funded Warrants to Purchase 909,091 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.: 333-232542 PROSPECTUS SUPPLEMENT (To Prospectus dated July 11, 2019) 7,590,909 Shares of Common Stock Pre-Funded Warrants to Purchase 909,091 Shares of Common Stock We are offering 7,590,909 shares of our common stock and, to certain investors in lieu thereof, pre-funded warrants to purchase 909,091 shares of our common sto |
|
| June 8, 2020 |
Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.: 333-232542 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and accompanying prospectu |
|
| June 8, 2020 |
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS EX-99.1 Exhibit 99.1 As used in this Exhibit 99.1, unless the context indicates otherwise, references to “Kezar,” “the Company,” “we,” “us,” “our” and similar references refer to Kezar Life Sciences, Inc. and its wholly owned Australian subsidiary, Kezar Life Sciences Australia Pty Ltd. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Exhibit 99.1 contains forward-looking statements. In some |
|
| June 8, 2020 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2020 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commiss |
|
| June 8, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.: 333-232542 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and accompanying prospectu |
|
| June 3, 2020 |
Kezar Provides Data Update from MISSION Study of KZR-616 Exhibit 99.1 Kezar Provides Data Update from MISSION Study of KZR-616 • Two of two patients with Lupus Nephritis saw greater than 50% reduction in proteinuria • KZR-616 demonstrates improvement on exploratory efficacy measures across seven measures of disease activity • Step-up dosing drives positive safety and tolerability profile SOUTH SAN FRANCISCO, Calif., June 3, 2020 - Kezar Life Sciences, I |
|
| June 3, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2020 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commission |
|
| May 7, 2020 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of the 14th day of January, 2020 (the “Effective Date”), between Vassiliki Economides (“Executive”) and KEZAR LIFE SCIENCES, INC. (the “Company”). Certain capitalized terms used in this Agreement are defined in Article 7. On the Effective Date, this Agreement amends, restates, repl |
|
| May 7, 2020 |
Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of the 25th day of April, 2020 (the “Effective Date”), between Noreen Henig, M.D. (“Executive”) and KEZAR LIFE SCIENCES, INC. (the “Company”). Certain capitalized terms used in this Agreement are defined in Article 7. RECITALS A.The Company is a biopharmaceutical company. B.The Com |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commission F |
|
| May 7, 2020 |
Kezar Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update Exhibit 99.1 Kezar Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update • Noreen R. Henig, MD appointed as Chief Medical Officer • Additional data from the ongoing Phase 1b portion of the MISSION study to be presented before the end of Q2 2020 • IND submission for KZR-261, a first-in-class protein secretion inhibitor, is on track for Q1 2021 • Cash, cash equivale |
|
| May 7, 2020 |
75 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38542 Kezar Life Sciences, Inc. |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| April 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2020 KEZAR LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38542 47-3366145 (state or other jurisdiction of incorporation) (Commission |
|
| April 9, 2020 |
Kezar Provides Statement Regarding COVID-19 Pandemic Exhibit 99.1 Kezar Provides Statement Regarding COVID-19 Pandemic SAN FRANCISCO, Calif., April 9, 2020 - Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today issued the following statement regarding the COVID-19 pandemic: We would like to express our sincer |
